Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Stock Is Sinking Today

By Keith Speights - Oct 25, 2019 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Questions about near-term prospects are weighing on the gene-sequencing stock.

What happened

Shares of Illumina (ILMN 8.77%) were sinking by 10.4% as of 11:30 a.m. EDT on Friday following the company's third-quarter earnings announcement after the market closed on Thursday. Although Illumina beat analysts' revenue and earnings estimates and raised its full-year earnings guidance, investors appear to be concerned about uncertainties for the company's near-term growth.

So what

There are plenty of questions for Illumina right now. The company's microarray revenue, which depends largely on sales to direct-to-consumer (DTC) personal genomics customers such as Ancestry and 23andMe, continues to slump. Illumina CEO Francis deSouza acknowledged in the company's Q3 conference call, "[W]e do not expect DTC to return to growth in the near term."

DNA with a reddish background

Image source: Getty Images.

The company is seeing what it called "downward pressure on the pull-through" from its desktop systems. This is related to lower consumables revenue from customers with Illumina's smaller gene-sequencing systems including MiSeq and NextSeq. However, deSouza said this resulted mainly from customers moving to more powerful platforms. This transition can cause short-term pain but should result in larger consumables sales over the long run.

Illumina's acquisition of Pacific Biosciences of California also appears to be in jeopardy. On Thursday, the United Kingdom's Competition and Markets Authority (CMA) announced a provisional decision to stop the merger of the companies. DeSouza said that Illumina continues to think the deal promotes competition and will engage in further discussions with the CMA.

Now what

Growth stocks tend to be very volatile when there is any uncertainty or questions about what's next. We're seeing that play out now with Illumina.

However, the most important thing for investors to realize with the current uncertainty for Illumina is that it is related primarily to the near term. The company's long-term growth prospects, fueled in large part by increased use of genomic sequencing in oncology and population genomics initiatives, remain very good.

Keith Speights owns shares of Illumina. The Motley Fool owns shares of and recommends Illumina. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$226.59 (8.77%) $18.27
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$8.36 (-4.89%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.